Premium
Intravenous iron administration is associated with reduced platelet counts in patients with chronic kidney disease
Author(s) -
Hazara A. M.,
Bhandari S.
Publication year - 2015
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12218
Subject(s) - medicine , kidney disease , platelet , prospective cohort study , iron deficiency , gastroenterology , surgery , urology , anemia
Summary What is known and objective In the management of anaemia associated with chronic kidney disease ( CKD ), optimal use of intravenous (i.v.) iron has a central role. It minimizes reliance on erythropoiesis‐stimulating agents ( ESA s) and may be beneficial in reducing overall cardiovascular risks through its effects on platelet counts ( PLT ). We have examined the effects of i.v. iron on PLT in patients with CKD . Methods Two hundred and three patients with CKD , referred to a single teaching hospital in UK for i.v. iron therapy, received low molecular‐weight iron dextran at a median dose of 1000 milligrams given over a median time of 2 h and 40 min. PLT at baseline were compared with the measurements taken during a 4‐month follow‐up period post‐infusion. Results PLT were checked at various points following i.v. iron treatment. Compared with baseline, mean reduction in PLT ranged between 10·1 and 23·6 (×10 9 /L) during consecutive 15‐days intervals post‐treatment. At the reference point of 90‐days post‐infusion, the drop in PLT was statistically significant ( P < 0·001). What is new and conclusion Low molecular‐weight iron dextran in patients with CKD leads to reduction in PLT . This reduction appears soon after treatment and is maximal after 3 months. Prospective data are required to confirm these findings and examine whether this translates to a reduction in thrombotic episodes.